Dossiers

Celestite, Mineral Dossier No. 6, Mineral Resources Consultative Committee, HMSO, London, 1973. 

The notification dossier may also contain a risk assessment prepared by the notifier. The precise contents of a notification will depend on, e.g., the quantity of the substance to be placed on the market and, to an extent, on the properties and uses of the substance. The thresholds for notification and a summary of the information requirements are given in Table 14.12. 

Decision recognizing the dossiers for the possible inclusion of mesotrione, lodosulfuron-methyl-sodium, silthiopham and ghocladium catenulatum in Annex I to Directive 91/414/EEC concerning the placing of plant-protection products on the market... 

The development of a single enantiomer as a new active substance should be described in the same manner as for any other new chemical entity. Studies should be carried out with the single enantiomer, but if development began with the race-mate then these studies may also be taken into account. Chiral conversion should be considered early on so that enantiospecific bioanalytical methods may be developed. These methods should be described in chemistry and pharmacy part of the dossier. If the opposite enantiomer is formed in vivo, then it should be evaluated in the same way as other metabolites. For endogenous human chiral compounds, enantiospecific analysis may not be necessary. The enantiomeric purity of the active ingredient used in preclinical and clinical studies should be stated. 

An Investigational Medicinal Product Dossier (IMPD) is intended to be more comprehensive than an IB, in that it should contain summaries of available quality data in addition to the safety and efficacy information that constitutes the main part of the IB. In total, it should provide information on the chemistry, manufacture, control and stability ofthe medicinal product, together with the results of non-clinical and clinical studies. In order to avoid repetition, the IB can be cross-referenced for non-clinical and clinical results. Ideally, the IMPD should follow the same structure as that which will be used later for the marketing authorisation application. For products with existing marketing authorisations, the Summary of Product Characteristics may replace the IMPD to varying extents (see Chapter 6). 

The content of the application is quite similar to EU requirements, although the structure and terminology is slightly different. The main headings are shown in Table 5.5. However, the FDA will now also accept IND application dossiers structured according to the CTD format (see Chapter 6 for the CTD format). 

Table 6.1 Relationship between CTD and previous EU dossier structure. ...

Regional Administrative Information Summary of the Dossier Administrative Summary of Product Characteristics 1 1 a lb... 

The CTD format has been incorporated into the E U regulations and is set out in the revised version of Annex I to directive 2001/82/EC, which was published as Commission Directive 2003/63/EC. It is also supported by detailed guidance in the Rules Governing Medicinal Products in the European Union, Volume 2B - Presentation and content of the dossier - CTD2001 edition. The relationship between the CTD format and the previous four-section format that was used in the E U is shown in Table 6.1. 

The applicant must submit complete copies of dossier to the EMEA, and directly to each of the rapporteurs. The EMEA are allowed 14 days to validate the application to ensure that it is complete and in accordance with the regulations, after which the rapporteurs can commence the scientific evaluation. The review process involves considerable feedback between the rapporteurs, the CHMP and the applicant, central to which can be achieving agreement on the final text of the SPC, labels and leaflet. The rapporteurs are required to deliver preliminary assessment reports to the CHMP within 80 days of the start of the review process. The applicant is also copied on the report. Over the next 40 days issues raised in... 

If the opinion is unfavourable, the applicant has 15 days to notify the agency of its intention to request a re-examination of the decision, and a further 45 days to submit the grounds on which a review is requested. New rapporteurs are appointed to re-examine the dossier, and the C H M P is allowed 60 days to deliver its opinion in light of the re-examination. 

Outside of the products that come within the scope of Community Authorisations, all other products can only be licensed via application to the Competent Authorities of individual Member States. However, through the use of either decentralised or mutual recognition procedures it is possible to obtain authorisations on the basis of a dossier assessment conducted by a single Member State. 

The decentralised procedure can be used in cases where the product has never been authorised in any of the Member States, and the applicant wishes to obtain a license in a number of states simultaneously. The applicant must submit applications with the complete dossier to the Competent Authorities of each of the Member States where authorisation is desired. A single Member State should be chosen as the reference state to undertake the scientific assessment ofthe complete dossier, while the other states are designated as concerned states. The review process has many parallels vhth the centralised procedure, in that similar time lines exist, the reference State plays the role ofthe rapporteur, and the concerned States replace the CHMP. Once all States have validated that the dossiers are complete, the reference State is allowed 70 days to review the dossier and prepare a preliminary assessment report, which is circulated to the concerned Member States and the applicant. Comments from the concerned Member States and applicant responses are collected so that by day 120 the reference State may issue a draft assessment report together vhth draft SPC, label and leaflet texts. The clock may be stopped until requested responses from the applicant are received. The application then enters the second step in the assessment process, during which all the concerned Member States consider the... 

Rapporteurs appointed (CHMP) Dossier Submitted (Applicant)... 

Reference to relevant study (including location in the dossier) ... 

The requirements for the contents of an application dossier are set out in Annex I of Directive 2001/82/EC. The dossier should be assembled in four parts, as outlined in Figure 7.6. The application form. Summary of Product Characteristics (SPC) and labelling, expert reports and quality sections are quite similar in content to human... 

Figure 7.6 Outline of the dossier structure for a marketing application for a veterinary product.

A dossier that focuses on quality (manufacture, control, stability) and labelling of the product must be submitted in support of the application. 

All other homeopathic and herbal medicines that do not qualify for simplified registration procedures will have to go through the standard authorisation procedure with supporting technical dossiers. The Committee for Herbal Medicinal Products has been charged with preparing monographs on herbal products so as to further facilitate the registration of traditional and well-established use herbal products. 

Generic authorisation Yes (SPC) Yes (CMC and stability) No (Reference dossier) No (Reference dossier)... 

EC Design-examination Certification Certification based on examination of the design dossier versus standards/essential requirements (paperwork review)... 

---